Advertisement
Supported by
The director, Dr. Francis Collins, took into account President Trump’s suggestion that a coronavirus vaccine would be available on Election Day. The Indonesian capital will reimpose the restrictions.
Transcription
I cannot say enough that resolutions on how this vaccine will be evaluated and evaluated will be based on science. And I know that I speak on behalf of my colleagues in government, and surely of the clinical network in general, that possibly this is the only basis on which this resolution is made. Otherwise, we wouldn’t be expecting the public to accept it as true with us. This will therefore be the only measure. Will it take place on a certain date? I probably can’t tell you now either because I don’t know what’s going to happen in the next few months. I am cautiously sure that by the end of 2020, at least one of those vaccines will have been released and proven to be safe and effective. But even that is a guess, and surely waiting for whether it will take place in a specific week before or after a specific date in early November is far beyond anything any scientist at this point can tell you, and be sure. they know what they know. Let’s say. So yes, science and science alone will be the way this resolution will be made. Otherwise, you might not have any stake.
Dr. Francis Collins, director of the National Institutes of Health, challenged President Trump’s suggestion Wednesday that a coronavirus vaccine would be obtained on Election Day, as he continually sought to reassure senators and the public that a vaccine would not be made. accessible to the public unless it is and effective.
“Certainly, waiting for this to happen a specific week before or after a specific date in early November is way beyond what any scientist right now can tell you and be sure you know what you’re saying,” Dr. Collins said. Senate panel at a hearing about the effort to locate a vaccine.
Wednesday’s hearing before the Senate Committee on Health, Education, Work and Pensions came amid growing fears about whether other people would hesitate to take a coronavirus vaccine and whether Trump would politically pressure his administration to temporarily approve one to give him. a spike in his run for re-election opposite former Vice President Joseph R. Biden Jr.
On Tuesday, an organization of pharmaceutical corporations involved in the race to expand vaccines promised not to publish any vaccines that did not meet strict standards of efficacy and protection. Hours later, a leading vaccine expander, AstraZeneca, announced that he had suspended a large clinical trial at the scale of a vaccine candidate after a patient experienced what could be a serious adverse reaction. Dr. Collins noted this progression as “a concrete example of how even a single case of unforeseen disease is sufficient to conduct a clinical trial in several countries”- and evidence that ” we are committed “to protection.
In an interview on CBS This Morning, Dr. Anthony S. Fauci, the government’s leading infection specialist, echoed this sentiment.
“That’s why you have other testing stages, to find out if those applicants are safe,” dr. Fauci said, adding that such a decision “is not unusual at all. “
At the hearing, panel Democrats questioned Dr. Collins and Surgeon General Jerome Adams about the effect of Collins’ false statements on the vaccine and whether they would erode confidence in the progression process. Collins, however, objected, while Senator Elizabeth Warren, a Massachusetts Democrat, bluntly asked her if Collins’ incorrect information was. Trump would deter others from taking the vaccine and undermine efforts to distribute it.
“I’m not sure I know the answer to that question,” said Dr. Collins. When Ms Warren pressed him again, he added, “I just hope that Americans get the data they want from scientists, not politicians. “
Three corporations are at a complex level of Phase 3 clinical trials that aim to recruit 30,000 Americans, some of whom will get the candidate vaccine and part of them will get a placebo.
Dr Collins said he was “cautiously optimistic” about a safe and effective vaccine until the end of the year, he added, “but even that’s an assumption. “
Even as trials progress, big questions arise about who will get a vaccine first and how it will be distributed. Adams told the panel that the administration intends to take into account the rules later Wednesday that would allow state-approved pharmacists to vaccinate those over the age of 3.
Advertisement